European Commission approves cemiplimab (Libtayo®) for the first-line treatment of patients with advanced non-small cell lung cancer with ≥50% PD-L1 expression

Approval of the PD-1 inhibitor for use in adults with metastatic or locally advanced disease who are not candidates for definitive chemoradiation was based on data from a Phase III trial (n=710), in which it extended median overall survival by 8 months versus chemotherapy.

Source:

Biospace Inc.